Literature DB >> 12183155

FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity.

Volker Brinkmann1, Kevin R Lynch.   

Abstract

The novel immunomodulator FTY720 is remarkably effective in models of transplantation and autoimmunity. Recent data show that phosphorylated FTY720 is an agonist at four sphingosine 1-phosphate receptors. Stimulation of sphingosine 1-phosphate receptors leads to sequestration of lymphocytes in secondary lymphatic tissues and thus away from inflammatory lesions and graft sites.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12183155     DOI： 10.1016/s0952-7915(02)00374-6

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  60 in total

1.  Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist.

Authors:  Hugh Rosen; Christopher Alfonso; Charles D Surh; Michael G McHeyzer-Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-03       Impact factor: 11.205

2.  Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.

Authors:  John M Kovarik; Robert Schmouder; Denise Barilla; Yibin Wang; Gerolf Kraus
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 3.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

4.  The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis.

Authors:  Manshu Sui; Jin Zhou; Rujuan Xie; Xiaogang Liu; Suhong Mu; Xibei Jia; Jing Ma; Hongchi Wu
Journal:  Mol Biol Rep       Date:  2011-08-11       Impact factor: 2.316

5.  FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal.

Authors:  Patricia A Taylor; Ryan M Kelly; Nick D Bade; Michelle J Smith; Heather E Stefanski; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-19       Impact factor: 5.742

Review 6.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 7.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 8.  Regulation of immunity by lysosphingolipids and their G protein-coupled receptors.

Authors:  Edward J Goetzl; Hugh Rosen
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches.

Authors:  Cornelia Halin; M Lucila Scimone; Roberto Bonasio; Jean-Marc Gauguet; Thorsten R Mempel; Elizabeth Quackenbush; Richard L Proia; Suzanne Mandala; Ulrich H von Andrian
Journal:  Blood       Date:  2005-05-03       Impact factor: 22.113

Review 10.  Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system.

Authors:  Edward J Goetzl; Wengang Wang; Christine McGiffert; Mei-Chuan Huang; Markus H Gräler
Journal:  J Cell Biochem       Date:  2004-08-15       Impact factor: 4.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.